Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
- Corvus presents preclinical data for soquelitinib at Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases.
- Next-gen ITK inhibitor candidates designed to modulate specific T cell subsets for various immunology indications.
- Soquelitinib demonstrates activity in six models of T cell-mediated inflammatory and immune diseases.
- Potential to treat atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, and more.
- Chemical structures of next-gen ITK inhibitors refined for specific biologic functions targeting different disease types.
- None.
Insights
The preclinical data for Corvus Pharmaceuticals' ITK inhibitor program, specifically soquelitinib, indicates a significant advancement in the modulation of T-cell responses across various immune-mediated diseases. The ability of these inhibitors to selectively target Th1, Th2 and Th17 cell functions could revolutionize the treatment of conditions like atopic dermatitis, asthma, psoriasis and rheumatoid arthritis. The specificity of these inhibitors suggests a tailored approach to immunomodulation, potentially reducing the side effects associated with broader immunosuppressive drugs.
From a research perspective, the development of such targeted therapies is critical. The data suggests these next-generation ITK inhibitors could offer a competitive advantage in the biopharmaceutical landscape. It is important to note that while preclinical models provide valuable insights, the transition to clinical efficacy in humans is not guaranteed and further trials will be essential to determine the safety and effectiveness of these compounds in a broader patient population.
Corvus Pharmaceuticals' focus on ITK inhibition could position the company at the forefront of a niche market within immunology treatments. The mention of advancing soquelitinib towards a Phase 3 trial for peripheral T cell lymphoma and a Phase 1 trial in atopic dermatitis indicates a strategic move to address unmet medical needs. This progression into later-stage clinical trials is often a catalyst for investor interest, as it signals a higher likelihood of product commercialization.
Investors should consider the potential market size for each indication and the competitive landscape. For instance, atopic dermatitis and asthma have substantial patient populations and existing treatments, which means successful entry into these markets could be lucrative but will require strategic positioning against established therapies. In contrast, rarer diseases like peripheral T cell lymphoma might offer faster regulatory pathways and less competition.
The advancement of Corvus Pharmaceuticals' ITK inhibitors, particularly soquelitinib, into later stages of clinical trials, could have significant financial implications. The costs associated with clinical development are substantial and the move towards a Phase 3 trial will likely increase R&D expenditures in the short term. However, if successful, the long-term revenue potential from multiple indications could offset these costs and provide a robust return on investment.
Investors should evaluate the company's current financial health, including cash reserves and burn rate, to ascertain its ability to fund these trials without the need for potentially dilutive financing. The potential for strategic partnerships or licensing agreements could also affect the financial outlook, depending on the terms and the stage at which they are secured.
Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications
BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
The poster presentation includes the first description of Corvus’ next-generation ITK inhibitor preclinical product candidates, which were designed to deliver precise T-cell modulation that is optimized for specific immunology indications. These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function. Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes. Th17 cells are associated with psoriasis and psoriatic arthritis. A Th1 immune response is strongly implicated in rheumatoid arthritis and protection from many infections. The Venn diagram in Figure 1 illustrates the potential ability of various ITK inhibitor preclinical candidates developed by Corvus (I-number indicates individual compounds; SQL represents soquelitinib) to modify the differentiation of T cells. These results suggest that chemical structures may be refined to perform more specific biologic functions and may enable targeting of various disease types.
Figure 1: Venn diagram illustrating different biological properties of the next-gen ITK inhibitors in T cell differentiation assays.
“We have established our leadership in ITK inhibition with the development of soquelitinib, which is advancing on track towards the initiation of a registration Phase 3 trial in relapsed peripheral T cell lymphoma and the initiation of a randomized, placebo-controlled Phase 1 trial in atopic dermatitis,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “We are building further on the connection between lymphoma and immune diseases, and the role of ITK inhibition. Our research has led to the development of next-generation inhibitors that are designed to precisely modulate specific T cell subset functions in order to potentially treat a range of diseases. The selectivity of these next generation ITK inhibitors gives Corvus options to choose between broad immunosuppression and highly targeted immunomodulation depending on the clinical indication.”
The preclinical data demonstrate that soquelitinib was active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease. This activity was shown to be the result of soquelitinib’s ability to impact disease-associated cytokines by targeting the cellular sources, specifically Th2 and Th17 cells, which produce various cytokines including IL-4, IL-5, IL-13 and IL-17. Some of the data from the poster presentation were recently published online in a preprint at bioRxiv.org.
The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia. The poster presentation is available on the Publications and Presentations page of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Corvus plans to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
About Soquelitinib
Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. The immunologic effects of soquelitinib lead to what is known as Th1 skewing and is made possible by the high selectivity of soquelitinib for ITK. Research on soquelitinib’s mechanism of action suggests that it has the potential to control differentiation of normal T helper cells and enhance immune responses to tumors by augmenting the generation of cytotoxic killer T cells and the production of cytokines that inhibit cancer cell survival. Soquelitinib has also been shown to prevent T cell exhaustion, a major limitation of current immunotherapy and CAR-T therapies. Optimal doses of soquelitinib have been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company plans to initiate a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company’s product candidates including soquelitinib, ciforadenant and mupadolimab; the potential use of soquelitinib to treat a variety of solid tumors, hematological cancers, as well as autoimmune and allergic diseases; and the potential of the Company’s next-generation ITK inhibitor preclinical product candidates. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2023, filed with the Securities and Exchange Commission on November 7, 2023, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of soquelitinib and its other product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4536b195-3481-4fb9-9bd3-db24486aafbd
FAQ
What was presented at the Keystone Symposia regarding Corvus Pharmaceuticals?
What are the next-generation ITK inhibitor candidates designed for?
What diseases are thought to be primarily mediated by Th2 lymphocytes?
What is the potential ability of various ITK inhibitor preclinical candidates developed by Corvus?
What diseases are associated with Th17 cells?
What immune response is strongly implicated in rheumatoid arthritis?
Who presented the preclinical data and information on Corvus' next-generation ITK inhibitor candidates?
What disease types did soquelitinib show activity in?
Where can the poster presentation be found?
